Mesoblast (MESO) Net Income towards Common Stockholders Growth (5y) (2020 - 2023)
Mesoblast (MESO) Net Income towards Common Stockholders Growth (5y) (2020 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Mesoblast | 19.81 Bn | 19.68 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -46.84% |
| Mar 31, 2023 | 23.58% |
| Dec 31, 2022 | 12.38% |
| Sep 30, 2022 | 34.57% |
| Jun 30, 2022 | -42.70% |
| Mar 31, 2022 | 47.09% |
| Dec 31, 2021 | -5.29% |
| Sep 30, 2021 | -56.18% |
| Jun 30, 2021 | -19.69% |
| Mar 31, 2021 | -52.80% |
| Dec 31, 2020 | -2.85% |